David Mclntosh: Expanding Plasma Protein Therapies in Underserved Regions
David McIntosh, Founder and Chair of United Plasma Action, shared a post by Generic Pharma Hub on LinkedIn:
“A Real Cause for Celebration
As the traditional annual Plasma Awareness Week rolls up, it is enormously refreshing to see this webinar included in the schedule.
Here we have a team actually addressing and confronting the key task – not of finding new ways to celebrate alleged success – but of actually changing the chronically inadequate Status Quo – AND to a quantified time-line.
The notion of asking what needs to be done to improve the global plasma medicines situation by or before 2035 may sound like standard good practice in any field with a currently sub-optimal performance, but it is in fact revolutionary – and it’s exactly what’s needed, right here, right now.
This event must surely be a vital part of the week’s activities for everyone with a serious interest in extending and improving the Plasma Community’s reach to the underserved majority of rare disease sufferers, worldwide.
It is estimated that some 80% of patients currently have little or no access to the life-saving and life-enhancing plasma-derived medicines that they so badly need.
It is to relieving their plight that we must surely dedicate our efforts in the years ahead.
The output from the October 6th webinar, will surely form an important part of that dedication!”
Generic Pharma Hub shared a post on LinkedIn:
“Prof. Thierry Burnouf has spent decades advancing the science of plasma fractionation, therapeutic plasma proteins and blood safety.
His work spans plasma protein purification, pathogen safety and the development of approaches to make plasma-derived medicinal products safer and more accessible, particularly in regions where access remains limited.
At Plasma 2035: Emerging Scene – Plasma Protein Therapy, he brings the scientific perspective to the conversation – connecting plasma resources, fractionation capability and safety with the larger challenge of ensuring these therapies ultimately reach patients.
Join us as we explore what needs to change by 2035 to make safe and effective plasma protein therapies more accessible, particularly in developing countries.
October 6, 2026
11:00 AM IST
Register.”
More posts featuring David McIntosh on Hemostasis Today.
-
Oct 2, 2026, 06:00Susan Wickersham: Gradual Shift towards Autologous Blood Transfusion is a Current Trend
-
Oct 2, 2026, 05:54Shamee Shastry: When Every Cell Reacts – The Hunt for Rare Blood
-
Oct 2, 2026, 05:38Dianne E. van der Wal: C-Terminal Endings Impact PAR1/PAR4 Peptide Potency in In Vitro Platelet Assays
-
Oct 2, 2026, 05:29Mohammed Alo: Your LDL Isn’t a Snapshot – It’s a Smoking Habit Measured in Years
-
Oct 2, 2026, 00:33Marwa Mostafa: Hemoglobinopathies – When Globin Genes Go Wrong
-
Oct 1, 2026, 23:46Behnood Bikdeli: Global Burden of Venous Thromboembolism
-
Oct 1, 2026, 23:46Sthanu Subramanian: Clinical Presentation, Risk Factors, Diagnosis, and Neuroimaging Findings in CVT
-
Oct 1, 2026, 23:45Martha Gulati: Oral MHT Is Associated With Increased Thrombotic Risk
-
Oct 1, 2026, 23:44Priya Sriskandarajah: HEMA-MED Trial Exploring Roginolisib Plus JAK Inhibitors in Myelofibrosis